Corvus Pharmaceuticals, Inc.

NasdaqGM CRVS

Corvus Pharmaceuticals, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 56,122,128

Corvus Pharmaceuticals, Inc. Shares (Diluted, Weighted) is 56,122,128 for the Trailing 12 Months (TTM) ending September 30, 2024, a 18.41% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.
  • Corvus Pharmaceuticals, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 47,394,587, a 1.81% change year over year.
  • Corvus Pharmaceuticals, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 46,553,121, a 23.91% change year over year.
  • Corvus Pharmaceuticals, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 37,570,909, a 27.65% change year over year.
  • Corvus Pharmaceuticals, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 29,433,800, a 0.42% change year over year.
Key data
Date Shares (Diluted, Weighted) Revenue Cost of Revenue Gross Profit
Market news
Loading...
NasdaqGM: CRVS

Corvus Pharmaceuticals, Inc.

CEO Dr. Richard A. Miller M.D.
IPO Date March 23, 2016
Location United States
Headquarters 863 Mitten Road
Employees 28
Sector Health Care
Industries
Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Similar companies

HOOK

HOOKIPA Pharma Inc.

USD 1.86

4.49%

INZY

Inozyme Pharma, Inc.

USD 1.51

-12.21%

MREO

Mereo BioPharma Group plc

USD 3.06

-8.38%

TERN

Terns Pharmaceuticals, Inc.

USD 4.57

-4.79%

ABOS

Acumen Pharmaceuticals, Inc.

USD 1.56

-1.89%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

PDSB

PDS Biotechnology Corporation

USD 1.39

-2.11%

StockViz Staff

January 16, 2025

Any question? Send us an email